Authors Instruction

  • Authors Instruction

    Section 1: Publishing Scope

    Journal of Shanghai Jiao Tong University (Medical Science) (monthly) is a well-known comprehensive academic journal of medicine and health in China. The aim of this journal is to guide the development of science and technology, cultivate academic talents and enhance academic exchanges. It publishes new achievements, theories, technologies and experiences in the fields of basic medicine, clinical medicine and public health. The journal welcomes innovative, high-level and significant original research papers, as well as literature review and informative articles reflecting the latest achievement of the discipline. The columns include original research articles (basic research, clinical research, public health, evidence-based medicine, techniques and methods), reviews, short articles, case reports, etc.

    Section 2: Requirement for Manuscript

    1.    General Requirement: Manuscript should be innovative, scientific, logical, accurate, normative and readable with clear viewpoint, sufficient argumentation, concise wording, reliable data, clear structure and standard writing. Generally, original research article shall not exceed 8,000 Chinese characters (including figures and tables). Short article shall not exceed 5,000 Chinese characters, and case report should not exceed 3,000 Chinese characters. Plagiarism, forgery, falsification, improper authorship and multiple submission is prohibited.

    2.    Title: Title should be concise and accurate, well reflecting the content of the article. Avoid uncommon acronym and do not exceed 26 Chinese characters. The English title should be the same as the Chinese one in content.

    3.    Authors: Beneath the title should be the authors’ names, institutes (specifying department), cities and post-codes both in Chinese and English. For the English version, surnames should be capitalized for every letter and for given names only the first letter capitalized. Authors from the same institute should be marked with the same Arabic number at the top-right corner. The same number should also be marked before the authors’ institute.

    4.    Abstract: All articles should include Chinese and English abstract. The Chinese abstract of original research article shall be more than 600 characters. The Chinese abstract of review shall be about 400 characters. Except review and case report, the abstract should be structural, including Objective, Methods, Results and Conclusion. The English abstract shall be strictly corresponding to the Chinese abstract in content. The abstract in both languages should be written in the third person perspective, avoiding using “the paper” and “the author” as subjects.

    5.    Footer: Following information should be stated at the footer of the first page of the article: funding project and its number; profile of the first author including name, birth date, gender, ethnic group (except for Han), professional title, degree and e-mail; the name and e-mail of the corresponding author.

    6.    Key Words: All articles should have 3~8 key words both in Chinese and English. Please try to use the words listed in the latest MEDLINE medical thesaurus (MeSH). The first key word must be a subject word from MeSH. If there is no suitable word in the latest version of MeSH, the author could (1) select several directly related subject words; (2) use the subject word of the direct higher level in the tree-diagram; (3) If necessary, conventional words can be used and placed at the end. Acronyms should be restored to full spelling according to MeSH. English key words should have the same meaning as the Chinese ones.

    7.    Terminology: Medical terms shall be selected from Medical Terms published by Science Press and reviewed by the National Scientific and Technical Terms Review and Approval Committee. For technical terms that have not yet passed the approval, authors could take reference to the latest version of MeSH, the Annotation Sequence of Medical Subject Words and the Subject Words List of Traditional Chinese Medicine. For terms without commonly-used translation, the original words shall be included in brackets when they appear for the first time in the manuscript. The names of Chinese and Western medicines shall be subject to the latest version of the Pharmacopoeia of the People's Republic of China and the General Names of Chinese Medicines (both issued by the Chinese Pharmacopoeia Committee). If it is necessary to use a trade name, its general name shall be stated first. For terms that have not been approved, authors can take reference to English-Chinese Medical Terms published by the People’s Medical Publishing House.

    8.    Format: The main body of an original research article should include four parts: Introduction, Materials & Methodology, Results and Discussion. Case report should include two parts: Clinical Data and Discussion. Article should be structured with a 3-level subheading system. The first level subheadings are preceded by “1, 2, 3…”; the second level subheadings preceded by “1.1, 1.2; 2.1, 2.2, …”; the third level subheadings preceded by “1.1.1,1.1.2…;2.1.1,2.1.2, …” Introduction shall not have subheading. If the method adopted has already been documented by a literature, a proper citation needs to be made. However, any revise or innovation on the documented method must be specified. The results could be summarized in words, figures or tables, but the content should not overlap. The full name of acronym should be stated in Chinese and English as it appears for the first time. Please refer to the articles published recently by the journal for format setting.
     
    9.    Figures and Tables: Figures and tables should be placed in the main body of the article and referred to in the preceding paragraph. The titles of figures and tables should be bilingual. The content and notes should only be in English. All tables shall adopt "three-line style". Each figure, table or formular shall be numbered respectively according to the order of appearing.
    (1) Font and size
    Chinese: Hanyishusongyijian (汉仪书宋一简) or Songti (宋体)
    English: Times New Roman
    8 pt

    (2) Layout
    Width maximum:174 mm
    Width for single column:84.5 mm
    Width for multi-column:174 mm
     
     

    (3) Drawings
    Lines of coordinate axis: 0.13 mm in width
    Lines of columns or curves 0.27 mm in width
    The original file in which lines and words can be modified should be provided (preferably in EMF format, other formats are acceptable such as EPS, VSG, visio, AI, Excel, DOCX, PPT, CDR, etc.)
     
     

    (4) Resolution
    Resolution refers to the number of pixels per unit length (area)
    At least 300 PPI (pixels per inch)
    When setting PPI, please ensure that the width of the picture meets the requirements

    (5) Figures of imaging apparatus
    Provide original images
    Do not stretch
    Tiff format
    Ensure the width and resolution meet the requirement
    The scale or magnification times should be indicated for pathological pictures. The ratio shall be marked in the lower right corner
    Dyeing method should be stated if applicable


    10.    Units and Symbols: The unit of measurement should comply with the provisions of the Legal Unit of Measurement of the People's Republic of China promulgated by the State Council in 1984 and shall be implemented and expressed in unit symbols. Please refer to the third edition of the Application of Legal Units of Measurement in Medicine issued by the Chinese Medical Association Journal Office (published in 2001). The statistical symbols shall usually be in italics and should comply with the Provisions of Statistical Vocabulary and Symbols (GB 3358.1-2009). Special attention should be paid to such cases as whether the letter is Romanic or Greek, capitalized, italic, upper marked, lower marked or not. A person’s name or terminology of the west should be in English instead of Chinese transliteration.   

    11.    Statements: All articles need to disclose competing interest at the end of the text and the authors contribution shall be stated at the end of the text. Article involving medical ethics (including human and animal rights) need to disclose the relevant information at the end of the text. Each statement adopts an independent first level subheading without numbering. For specific requirements, please refer to the section "Competing Interest", "Authors Contribution" and "Medical Ethics". The above statements and subheadings should be both Chinese and English.

    12.    References: References are publications that have been directly cited in the article. 80% of them should have been published in the last five years. The cited literatures should be marked with Arabic numerals according to the order in which it appears in the text and be arranged accordingly at the end of the manuscript. An upper-right marker of the same number should be inserted in the corresponding place in the paragraph. Vancouver format shall be adopted.
    For each reference, only the first three authors are listed, followed by "et al." if there are more than three. For author’s names in roman letters, the surname should be placed in the front, with the initial letter of the given name being put at the back without a dot. Format of some common reference types are listed below. For other formats, please refer to relevant national standard (GB / T 7714-2015). Chinese references shall be translated into English under the same order number and the English shall be placed beneath the Chinese. For example,
    1)    Journal: Author. Title[J]. Journal, Year, Vol (No.): Page range.
    [1] 赵艳娜, 邱荣, 沈南, 等. 构建反转录病毒小向导RNA表达载体用于小鼠T细胞基因功能研究[J]. 上海交通大学学报(医学版), 2020, 40(12): 1585-1590.
    ZHAO Y N, QIU R, SHEN N, et al. Construction of retroviral small guide RNA expression vector for studying gene function of mouse T cells[J]. J Shanghai Jiao Tong Univ (Med Sci), 2020, 40(12): 1585-1590.
    2)    Book: Author. Book title. Edition [M] (not needed for the 1st edition). Place: Publisher, Year: Page range.
    [2] 章雅青. PBL-情境-模拟综合案例护理教程[M]. 北京: 人民卫生出版社, 2015: 1-3.
    ZHANG Y Q. PBL-situation-simulation comprehensive case nursing course[M]. Beijing: People's Medical Publishing House, 2015: 1-3.
    3)    Proceedings Extract: Author. Article title [C]. Editor (if any). Proceeding title. Place: Publisher, Year: Page range.
     [3] JIA C, LI C L, YING Z. Facial expression recognition based on the ensemble learning of CNNs[C]//2020 IEEE International Conference on Signal Processing, Communications and Computing (ICSPCC). Macao, China: IEEE, 2020: 1-5.
    4)    Dissertation: Author. Title [D]. Place: Institute, Year.
    [4] 金海燕. 焦虑障碍患者内感知觉特征的功能影像学研究[D]. 上海: 上海交通大学, 2020.
    JIN H Y. The characteristics and neural mechanism of interoception of patients with anxiety disorder[D]. Shanghai: Shanghai Jiao Tong University, 2020.
    5)    Patent: Patentee. Patent title: Patent Number [P]. Date of issue.
    示例:[5] KOSEKI A, MOMOSE H, KAWAHITO M, et al. Compiler: US828402[P]. 2002-05-25.
    6)    S&T Report: Author. Title [R]. Place: Publisher, Year: Page range.
    [6] World Health Organization. Factors regulating the immune response: report of WHO Scientific Group[R]. Geneva: WHO, 1970.
    7)    Electronic Resource: Author. Title [EB/OL]. (Date of publishing or updating) [date of citing]. Address of Electronic Literature.
    [7] Center for Bioengineering Innovation & Design, Johns Hopkins University. Why the CBID program at Johns Hopkins University is special?[EB/OL]. [2021-11-29]. https://cbid.bme.jhu.edu/academics/graduate-studies/what-makes-cbid-program-special/.

    Section 3: Ethics

    1.    Plagiarism: This journal only accepts original articles that have not been published before, and the manuscripts submitted shall not contain any plagiarized content. All manuscripts would be tested by the Academic Misconduct Literature Check (AMLC) system. Should any plagiarism be verified, the editorial office will immediately reject the manuscript. Any content overlapping with existing published works must have all necessary permissions and must be marked clearly in the manuscript.

    2.    Misconduct: Academic misconduct such as plagiarism, multiple submission or redundant publishing (including submission of the same content in different languages), data falsification and reference manipulation is strictly prohibited. Should any misconduct be verified, the editorial office will immediately reject the manuscript and all submission from the authors ever since. Moreover, we will send a notice to other journals in this field and to the author’s institutes. The practice of processing misconduct follows the guidelines of COPE.

    3.    Authorship: The order of authors shall be collectively determined before submission and shall not be changed thereafter. If truly necessary, the order of authors could be changed if a testimony unanimously signed by all authors is provided. An author should be a person who: (1) participates in topic selection, study design or data analysis and interpretation; (2) drafts or revises key theories or other main content of the paper; (3) reviews and revises the paper according to the comment from the editorial office, discusses it in academic community, and finally agrees on publishing; (4) besides his/her own research contribution, agrees to take responsibility for the integrity of all parts of the work. All the four conditions above must be met. Those who only participate in laboratory assistance, obtaining funds, collecting materials, or only managing the research team cannot be named as authors. The authors should download the Copyright License & Authors Contribution Form in the column of “Author” of this website, have it completed and signed by all authors, and provide it along with the manuscript. The authors are also required to disclose the information bilingually under a subheading of Authors Contribution at the end of the article.

    4.    Medical Ethics: The ethical issue and informed consent of the study must comply with common principles of medical ethics. When research participants are humans, the author should explain whether its procedure comply with the ethical standards formulated by a relevant committee (institutional, regional or national) responsible for human trials. The approval document of the committee should be submitted (the approval number should be included in the article). Consent letter from research participants or their relatives must be obtained, but not submitted to the editorial office. When reporting animal experiments, the study should comply with guidelines published by relevant committees on animal rights, and the approval document should be submitted. New original treating or operation method must also be approved by a relevant committee. All ethical matters mentioned above should be clearly stated at the end of the manuscript. The authors also need try their best to protect the privacy of the patients by pixelating the patients’ faces and avoiding revealing the patients’ confidential information such as names and IDs in images or specimens. The authors are also required to disclose the relevant information bilingually under a subheading of Ethics Approval and Patient Consent or Ethics Approval and Animal Right at the end of the article.

    5.    Trial Registration: Clinical trials must include the Universal Trial Number (UTN) obtained from one of the Primary Registries in the WHO Registry Network. The UTN shall be put at the end of the article, with a subheading of  “Trial registration”, specifying registry institution and UTN.

    6.    Reporting Guidelines:Authors are encouraged to follow medical reporting guidelines because they help authors describe the study in enough detail for it to be evaluated by editors, reviewers, readers, and other researchers evaluating the medical literature. Reporting guidelines have been developed for different study designs; examples include CONSORT for randomized trials, STROBE for observational studies, PRISMA for systematic reviews and meta-analyses, and STARD for studies of diagnostic accuracy. Authors are encouraged to describe the methods used for locating, selecting, extracting, and synthesizing data. This is mandatory for systematic reviews. Good sources for reporting guidelines are the EQUATOR Network (www.equator-network.org/home/) and the NLM's Research Reporting Guidelines and Initiatives
    (www.nlm.nih.gov/services/research_report_guide.html).

    7.    Competing Interest: All authors must disclose all potential conflicts of interest, i.e., when the financing/personal status/affiliation of the authors (or the authors' organization/employer) may affect the authors' decision, work or manuscript. When a product is mentioned, the author should also disclose whether there is a conflict of interest against competitive products. The authors should download the Statement of Competing Interests in the column of “Author” of this website, make a self-check term by term, have it signed by all authors and provide it along with the manuscript. The authors are also required to disclose the information bilingually under a subheading of Conflict of Interests at the end of the article. The author should state “there is no conflict of interest” even if there isn’t any conflict.


    Section 4: Peer Review & Editing

    1.    Review Policy: The journal follows a double-blind review process. After submission, the editorial office will conduct a preliminary review of the manuscript. The editorial office will reject the manuscripts which are insufficient in originality, having serious scientific or technical mistakes, lacking valuable information, or not in the scope of the journal. The manuscripts which have passed the preliminary review will be anonymously sent to two or more reviewers. The editor-in-chief will conduct the final round of review and the editorial office shall impartially select manuscripts on the basis of academic quality and the review comment. The authors must respond to the reviewers' every comment and submit the revised version in time. This process would be repeated until the reviewers and editors are satisfied with the manuscript.

    2.    Editorial Policy: All authors shall be responsible for their own writing. For the accepted manuscripts, the journal may make some technical or wording amendments. However, if the amendment involves a change of meaning, the editorial office will contact the authors for confirmation.

    3.    Review and Editing Process:
    (1) Submission: The authors submit the manuscript online and will receive a confirmation email.
    (2) Receipt: The editor receives the manuscript, sets a serial number and sends the number to the author via email.
    (3) Preliminary review: The editor conducts a preliminary review. If passed, the manuscript will be sent out for external review.
    (4) External review: The manuscript will be reviewed by at least two reviewers.
    (5) Final review: The editor-in-chief will make the final decision (accept/modify/reject) taking into consideration the comments of external reviewers.
    (6) Editing: The accepted manuscript will be edited, typeset and published.
    Authors can contact the editorial office for any question on submission.

    4.    Timing: The editorial office will notify authors of the review result within 3 months after submission, during which time the authors cannot re-submit the manuscript to other journals. If authors do not receive any feedback within 3 months, they can withdraw the submission or re-submit the manuscript to another journal after they confirm with the editorial office. The editorial office will notify the authors in time once the decision is made. If authors cannot return the revised manuscript within the time prescribed, they have to apply for an extension. Unjustified delay of revision will be regarded as withdrawn of submission.   

    5.    Submission by Editors: The editorial staff / editors / editorial board members should not be involved in publishing decisions on papers which they have written themselves or have been written by their family members or colleagues. Any such submission should be strictly subject to the journal’s usual editorial process. Peer review should be handled independently from the relevant author/editor and their research groups.

    6.    Appeal: The authors may make an appeal if they disagree with the comment of the reviewers. The authors need to write an appeal letter (with the manuscript serial number) and send it to xuebao@shsmu.edu.cn. Detailed reasons for appealing must be stated, including a comprehensive and reasonable answer to the reviewers’ comment. The appeal letter should also be stamped by the author’s institute. The editorial department will consider whether to change the decision case by case.

    Section 5: Correction and Retraction.

    1.    General Situation: Articles published online or in print are considered the final and complete version. In principle, the journal does not make corrections or retractions on published articles. However, in case of the situations described below, corrections or retractions may be carried out if truly necessary.

    2.    Correction: If there appears to be an unintended scientific mistake in the article which would not lead to significant impacts on the results and conclusions, the editorial office will publish corrections in the journal as soon as possible, detailing the changes made to the original article and indicating the source of the article. The journal will release the corrected new version of the article, and specify the changes to the original article and the date of update. In addition, the superseded version will also be archived. Readers can obtain it directly, but only the latest version of the article should be used for citation.

    3.    Retraction: In the following cases, the editorial office would retract published articles and issue retraction statements:
    1) If an article is found to have severe scientific errors making the results and conclusions of the article unreliable;
    2) For article suspected of academic misconduct, such as plagiarism and data falsification, the editorial office will initiate an investigation and issue a statement to inform readers of the risks associated with the article. Once the investigation is completed, the result will be made public. If the academic misconduct is confirmed, the article will be immediately retracted and a retraction statement will be issued by the editorial office.

    Section 6: Copyright and Archive

    1.    OA Policy: Journal of Shanghai Jiao Tong University (Medical Science) is an open access journal. Once published, all articles will be immediately and permanently available for readers to read and download free of charge. For more information, please refer to the Open Access Policy page on this website.

    2.    Copyright: Authors agree to license the copyright free of charge to the editorial office of the journal and Shanghai Jiao Tong University. The editorial office and the university have, but are not limited to, the following exclusive rights to use part or all of the content of the submitted manuscript: compilation, issuing, reproduction, translation and internet distribution. The editorial office and the university have the right to license the indexation by any literature retrieval systems, networks or databases. The journal and the university also have the right to publish and use this article through various media and or in any other language; All authors must sign the Copyright License and Authors Contribution Form and provide it along with the manuscript.

    3.    Retrieve and Download: The full text of all published articles could be retrieved and downloaded from the official website of the journal. In addition, the articles have also been indexed by the databases mentioned in “About Journal”. The full text can also be downloaded through the third party platforms such as CNKI, WANGFANG DATA, Weipu, Chinese Science Citation Database (CSCD), Chaoxing Library, SCOPUS and EBSCO.

    4.    Archive: Since July 2009, all journal articles have been digitally archived and can be searched and downloaded from the journal website. In order to ensure data security, all information has also been backed up in the editorial office. Before June 2009, the printing copy of each issue of the journal had been kept in the editorial office for archiving. If the journal and the website were closed, archiving data could be retrieved through third party full-text databases such as CNKI, WANFANG and Weipu, Chinese Science Citation Database (CSCD), Chaoxing Library, SCOPUS and EBSCO.

    5.    Data Sharing: The authors are encouraged to publish or share their research data whenever appropriate. Data sharing is helpful for experiment repeating and data reuse. The data for sharing may include original data, observation records, experimental results, etc. The journal also encourages the sharing of software, code, models, algorithms, protocols, methods and other useful materials. The authors can upload the materials above to an accessible third-party repository and make a proper citation or add a link at the end of the article.

    Section 7: Fees

    Once the manuscript publishing is confirmed, a fee shall be payable, which will be specified in a publishing notice (RMB 400 per page). After publishing, two free copies of the current issue shall be posted to the author.


    Section 8: Method of Submission

    Visit our website(http://xuebao.shsmu.edu.cn), sign in and make online submission. You can check your status via the online system or the journal’s WeChat platform.

  • 2019-12-05 Visited: 91274